Locations:
Search IconSearch
January 19, 2016/Cancer/News & Insight

Why Value-Based Cancer Care Can’t Wait

Reducing time to treatment is good for patients and the healthcare system

time_60x450

Physicians and patients don’t always agree on which outcomes are most important in cancer care. An example is the amount of time it takes to initiate treatment after a solid tumor diagnosis. Shortening the time-to-treat interval wouldn’t impact the medical outcome in the view of most oncologists, but to an anxious cancer patient, any wait is too long. And with medical value (and reimbursement) increasingly tied to delivery of patient-centered, timely care, the oncology community must embrace initiatives to quantify and improve these issues.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

bolwell0_150x180
Khorana_150x180

In this viewpoint article in the Journal of the National Comprehensive Cancer Network, Cleveland Clinic Taussig Cancer Institute Chairman Brian J. Bolwell, MD, and Vice-Chair for Clinical Services and Strategy Alok A. Khorana, MD, make the case for value-based, patient-focused cancer care and describe Cleveland Clinic Cancer Center’s initial efforts to shorten time to treatment using integrated practice techniques.

Photo Credit: ©Russell Lee

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad